A DECISION-ANALYSIS OF ALTERNATIVE TREATMENT STRATEGIES FOR CLINICALLY LOCALIZED PROSTATE-CANCER

Objective.-To model the impact of initial therapy on outcomes for men with localized (clinical stage A or B) prostatic carcinoma. Design.-A decision analysis modeling three strategies: radical prostatectomy, ex ternal-beam radiation therapy, and watchful waiting, with delayed horm onal therapy if metastatic disease develops. We modeled the main benef it of treatment as a reduction in the chance of death or disutility fr om metastatic disease. These benefits were offset in the model by the risks of treatment-related morbidity and mortality. The model was used to analyze expected outcomes by tumor grade (well, moderately, and po orly differentiated) for men 60 to 75 years of age. Data.-Probabilitie s and rates for important clinical events, obtained through review of the literature for prostatic carcinoma and analysis of Medicare claims data. Main Results.-Several patterns emerged within the range of unce rtainty about the risks and benefits of treatment for prostatic carcin oma. In patients with well-differentiated tumor grades, based on clini cal staging, treatment at best offers limited benefit in terms of qual ity-adjusted life expectancy and may result in harm to the patient. Am ong patients with moderately or poorly differentiated tumors, if we us e the most optimistic assumptions about treatment efficacy, then patie nts aged 60 to 65 years would benefit from either radical prostatectom y or external-beam radiation therapy, compared with watchful waiting. However, in most other cases, treatment offers less than a 1-year impr ovement in quality-adjusted life expectancy or decreases the quality-a djusted life expectancy compared with watchful waiting. Invasive treat ment generally appears to be harmful for patients older than 70 years. Conclusions.-Radical prostatectomy and radiation therapy may benefit selected groups of patients with localized prostate cancer, particular ly younger patients with higher-grade tumors. However, our model shows that in most cases the potential benefits of therapy are small enough that the choice of therapy is sensitive to the patient's preferences for various outcomes and discounting. The choice of watchful waiting i s a reasonable alternative to invasive treatment for many men with loc alized prostatic carcinoma.